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Introduction 
Attitudes towards the use of psychotropic medications for 
common mental disorders are an important aspect of ‘mental 
health literacy’ – that is, public knowledge and beliefs 
about mental disorders which aid their recognition, management 
or prevention (Jorm et al., 1997; Jorm, 2000). 
Attitudes towards commonly prescribed psychotropic medications 
(e.g. anti-depressants such as SSRIs; psychostimulants 
such as methylphenidate) may influence people’s 
willingness to start using these drugs, to continue using 
them, and to support their use by family and friends. These 
attitudes reflect broader cultural beliefs about the causes 
of mental illness and those who are affected by these 
disorders. 
 
In Australia, the use of pharmacological treatments for 
mental disorders has increased over the last decade. In the 
5 years to 2007, the use of prescription anti-depressants 
increased by 41% (Hollingworth et al., 2010). Between 
2002 and 2009 the number of stimulants that were dispensed 
(typically to treat attention deficit hyperactivity 
disorder – ADHD) increased by 87% (Hollingworth et al., 
2011). Public attitudes towards the use of psychotropic 
drugs have often been less positive than those of health care 
professionals, thereby posing a potential challenge to the 
use of these cost-effective and evidence-based treatments 
(Jorm et al., 2005). This paper explores the attitudes of 
members of the general public in Australia towards the 
acceptability of using prescription drugs to treat two common 
mental disorders, depression and ADHD, that are 
often treated with pharmaceutical drugs. 
 
Surveys of the US public show an increase in the 
endorsement of medications for the treatment of several 
mental illnesses, but attitudes towards the use of prescription 
drugs are not uniform across disorders 
(Pescosolido et al., 2010). This is probably for a number 
of reasons, such as variations in the perceived risk/benefit 
profile of the drug; in the perceived effectiveness of 
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non-pharmacological treatments; in beliefs about the 
aetiology of the disorder; and in the extent to which the 
condition is seen as a ‘brain disease’ rather than as the 
result of lifestyle, behavioural choices, and ‘character’ 
(Pescosolido et al., 2010). US surveys have not tended to 
explore attitudes towards the overall acceptability of 
using prescription drugs to treat depression and ADHD. 
Acceptability may be a good reflection of how members 
of the public weigh up the risks and benefits of pharmacological 
treatment and their views about the aetiology of 
the disorder. 
 
 
 
In Australia, public views about the use of anti-depressants 
have become more positive since the 1990s, although 
some scepticism about their use is evident. A 1995 national 
survey of Australian adults found that only 29% thought 
medications would be helpful in treating depression but this 
increased in the two subsequent decades to almost 48% in 
2003–2004 and to 59% in 2011 (Jorm et al., 2006; Reavley 
and Jorm, 2011). Despite these increases, more members of 
the public rated counselling, self-help, relaxation and close 
friends/family as helpful, and approximately 20% said antidepressants 
were actually harmful (down from 42% in 
1995 and 27% in 2003–2004) (Reavley and Jorm, 2011, 
2012). A 2002 survey of 900 community members across 
Australia found that 65% thought anti-depressants were 
helpful in treating depression, but nonetheless only 2% said 
that pharmacological therapy would be their first choice of 
treatment (Highet et al., 2002). 
 
 
There is comparatively little recent work on the attitudes 
of members of the Australian public towards the use of psychostimulants 
in the treatment of ADHD. Most surveys 
have focused on the attitudes of health professionals, school 
personnel and the parents of children with ADHD. A 2002 
US survey of the general public found that two-thirds had 
heard of ADHD and, among them, 78% thought it was a 
genuine disorder (McLeod et al., 2007). However, as with 
depression, participants preferred non-pharmacological 
interventions over medication. An earlier study of over 
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1000 members of the US public found that less than a third 
would medicate a child with ADHD (McLeod et al., 2004). 
In a survey of over 600 Australian parents, 77% said they 
believed ADHD is a genuine disorder but around two-thirds 
also believed it was over-diagnosed and thought that too 
many children with ADHD were treated with medication 
(Gilmore, 2010). 
 
 
A recent survey found that most Australian parents knew 
someone with ADHD either through colleagues or friends 
(40%), or in their own family (28%), but almost a third of 
parents had no contact with someone with ADHD (Gilmore, 
2010). Those with some contact were more likely to think 
that too many children are medicated for ADHD. The influence 
of such contact on attitudes towards the use of medication 
is not always clear in studies in other countries. Some 
surveys have found that parents with a child with ADHD 
favour behavioural rather than pharmaceutical treatments 
(Corkum et al., 1999) but others have found that parents of 
children with ADHD rated stimulant treatment more positively 
than parents of non-ADHD children (Stroh et al., 
2008). 
 
 
 
Australian surveys have found that more people report 
personal familiarity with depression than ADHD, with 
most indicating that either they or a family member have 
experienced depression (Highet et al., 2002). Familiarity 
with depression may have a more positive effect on attitudes 
towards the use of medications since Jorm et al. 
(2005) found that those who viewed anti-depressants as 
harmful were less likely to know someone with the disorder. 
Similar results have been found in other countries (e.g. 
Dahlberg et al., 2008). 
 
 
 
In this study we explored the general public’s attitudes 
towards the acceptability of using prescription drugs to 
treat depression and ADHD. This approach allowed us to 
take a broader perspective than would be possible by separately 
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measuring attitudes towards specific aspects of 
prescription drug use such as ‘helpfulness’ or ‘harmfulness’, 
or ‘preferred first choice of therapy’. The first aim 
of this study was to explore whether the public viewed 
pharmacological treatments for depression and ADHD as 
acceptable, and to what extent attitudes were similar for 
the two disorders. We also asked about participants’ 
familiarity with people who have been treated for these 
two conditions using prescription drugs (e.g. have you or 
anyone you know personally been treated for depression/ 
ADHD with prescription drugs?). The second aim was to 
explore how ‘familiarity’ was related to attitudes on the 
acceptability of pharmacological treatment for depression 
and ADHD. 
 
 
Method 
 
 
Sample 
 
 
The sample comprised 1265 participants: 633 males and 
632 females (aged 18+ years; range 18–101; mean = 53.7). 
Younger people were under-sampled when compared with 
the Australian Bureau of Statistics (ABS) census data for the 
Queensland population. Those aged under 35 years comprised 
13.9% of the sample (vs 30.6% ABS), those aged 
35–54 years comprised 35.1% (vs 38% ABS), and those 
aged 55+ years comprised 50.3% (vs 31.4% ABS). The 
sample varied in the number of years of education: 1–10 
(24.3%), 11–12 (22.5%), 13–14 (10.9%), and 15+ (41.2%). 
 
 
The survey instrument: The Queensland 
Social Survey 
 
 
Data collection was during July and August 2011 through 
the Queensland Social Survey (QSS), which is an omnibus 
style state-wide survey of households in the state of 
Queensland, Australia. The QSS is administered through a 
CATI (computer-assisted telephone interviewing) system at 
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Central Queensland University. It includes questions from 
multiple research bodies and other organizations on a wide 
range of topics. Among the questions participants were 
asked, we included two on the extent to which they agreed 
with the following statements: 
Q1. It is acceptable for prescription drugs, such as Prozac, to 
be used in the treatment of depression. 
Q2. It is acceptable for prescription drugs, such as Ritalin, to 
be used in the treatment of ADHD (attention deficit 
hyperactivity disorder). 
 
 
Participants were asked to respond using the following 
response categories: (1) strongly agree; (2) agree; (3) 
slightly agree; (4) neither agree nor disagree; (5) slightly 
disagree; (6) disagree; (7) strongly disagree; (8) don’t 
know. In Australia, Prozac and Ritalin are widely prescribed 
for the treatment of depression and ADHD, respectively, 
and are commonly mentioned in the media discourse 
about these conditions; we mentioned them by name to aid 
participant understanding. 
Next, we asked participants about their familiarity with 
persons who have been treated for depression or ADHD 
with prescription drugs: 
 
 
Q3. Have you, or someone you know personally, ever been 
treated for depression with prescription drugs? 
Q4. Have you, or someone you know personally, ever been 
treated for ADHD with prescription drugs? 
Participants were asked to answer according to the following 
format: (1) yes – I have; (2) yes – someone I know 
personally has; (3) yes – both myself and someone I know 
personally; (4) no; (5) don’t know. 
 
 
Procedure 
 
 
The target population for the telephone interview consisted 
of persons 18 years of age or older who, at the time of the 
survey, were living in a dwelling unit in Queensland and 
could be contacted by direct-dialled, land-based telephone 
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service. The response rate was 31.9%. The sample was 
drawn from a telephone database by using a computer program 
to select a random sample of phone numbers. Within 
the household, one eligible person was selected as the 
respondent for the interview. The respondent within each 
household was selected on the basis of gender using the 
following selection guidelines to ensure an equal yet random 
selection of male and female participants: 
1. The dwelling unit must be the person’s usual place 
of residence and he/she must be 18 years of age or 
older; 
2. Each household was randomly pre-selected as either 
a male or female household; 
3. If there was more than one male/female in the household 
then the male/female that had the most recent 
birthday was selected; 
4. If there was no-one of the pre-selected gender residing 
in the house then the house was designated not 
qualified. 
 
 
Analysis 
 
 
Participant responses to Q1 and Q2 were coded into four 
categories (Agree; Disagree; Neutral; Don’t know). 
Responses to Q3 and Q4 were coded into three groups 
(Not familiar; Yes – other (i.e. I personally know someone 
who has been treated with prescription drugs for that disorder); 
Yes – me (i.e. I have been treated with prescription 
drugs for that disorder)). Descriptive analyses gave overall 
rates of agreement with the acceptability of using prescription 
drugs to treat depression and ADHD, and overall rates 
of familiarity with drug treatment for depression and 
ADHD. 
 
 
We conducted two logistic regression analyses (one for 
depression and one for ADHD) to predict agreement with 
the acceptability of using prescription drugs to treat the disorder. 
In these models, participants who responded ‘Don’t 
know’ or ‘Neutral’ were excluded. The dependent variable 
was ‘Agreement with the acceptability of using prescription 
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drugs’ coded as disagree = 0; agree = 1. The predictor 
variables were: familiarity with the relevant disorder (not 
familiar = 0 (ref); yes – other = 1; yes – me = 2); gender 
(male = 0 (ref); female = 1); years of education (1–10 years 
= 0 (ref); 11–12 years = 1; 13–14 years = 2; 15 years+ = 3); 
and age (entered as a continuous variable). 
Using the same method, we conducted two logistic 
regression analyses (one for depression and one for ADHD) 
to predict actually having an opinion about the acceptability 
of using prescription drugs to treat the relevant disorder, 
as opposed to answering ‘Don’t know’ / ‘Neutral’. In these 
models, participants answering ‘Neutral’ and ‘Don’t know’ 
were combined, and compared to participants who agreed 
or disagreed (i.e. they expressed a firm opinion pro or con). 
The dependent variable was ‘Having an opinion’, coded as 
no opinion = 0; opinion = 1. The predictor variables were 
the same as above. 
 
 
Results 
 
 
A majority of participants said that it was acceptable to use 
prescription drugs to treat depression (55.5%); only 15.1% 
expressed outright disagreement. By contrast, attitudes 
towards the use of prescription drugs to treat ADHD were 
much less positive, with about the same proportion saying it 
was acceptable (35.6%) as unacceptable (35.7%) (Figure 1). 
For both depression and ADHD, almost one in five participants 
answered ‘Don’t know’ (19.8% for depression and 
19.5% for ADHD) and a smaller proportion indicated that 
their opinion was neutral (i.e. that they neither agreed nor 
disagreed). 
 
 
There were some interesting patterns of association 
between positive and negative attitudes towards using 
drugs to treat the two disorders. The great majority (80%) 
of those who thought drug treatment was acceptable for 
ADHD also thought that drug treatment was acceptable for 
depression and 70.1% of participants who disagreed with 
drug treatment for depression also disagreed with treating 
ADHD with drugs. But support for drug treatment of 
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depression did not necessarily translate into support for 
drug treatment of ADHD. Indeed, only 51.1% of those who 
agreed with drug treatment for depression thought that drug 
treatment for ADHD was acceptable. 
 
 
Depression 
 
 
Familiarity. Almost two-thirds of all participants were 
familiar with someone treated for depression (65.4%) in 
that they had either been treated for depression with prescription 
drugs (20.2%) or personally knew someone who 
had (45.2%). The remainder (34.5 %) did not know anyone 
who had been treated for depression with prescription 
drugs (26.1% of all female participants, and 46% of all 
males). 
 
 
Table 1 shows that participants in the ‘Not familiar’ 
group (39.1%) had a lower rate of agreement with the use 
of prescription drugs to treat depression, compared to those 
who knew someone who had been treated (62.4%), or those 
who had been treated themselves (68%). More participants 
in the ‘Not familiar’ group also answered ‘Don’t know’ 
(31.8%) compared to participants who either knew someone 
who had been treated with drugs for depression or who 
had been treated themselves. 
 
 
Figure 1. Responses to the statement ‘It is acceptable for 
prescription drugs to be used in the treatment of depression 
and ADHD’. 
 
Table 1. Agreement with the statement ‘It is acceptable for prescription drugs 
to be used in the treatment of depression’ according 
to familiarity with treatment for depression with prescription drugs. 
 
 
 
Predicting positive attitudes towards the acceptability of drug 
treatment for depression. A logistic regression analysis 
was used to assess the impact of a number of factors on the 
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likelihood that participants would agree with the acceptability 
of using prescription drugs to treat depression. The 
full model was able to distinguish between respondents 
who expressed outright agreement, and those who 
expressed outright disagreement, with the use of drugs to 
treat depression (χ2 (7, n = 886) = 40.185, p < 0.001). Table 
2a shows that familiarity and education were significant 
predictors while age and gender were not. Compared to 
those with no familiarity, participants who had been treated 
for depression with prescription drugs were 2.6 times more 
likely to agree that drug treatment for depression was 
acceptable. Those who personally knew someone who had 
been treated with drugs for depression were 1.7 times more 
likely to agree with drug treatment than those with no 
familiarity. A higher level of education also predicted 
agreement with the acceptability of drug treatment for 
depression. Compared to those with 1–10 years of education, 
participants with 15 or more years of education were 
2.2 times more likely to agree that drug treatment for 
depression is acceptable (participants with 11–12 years of 
education were 1.75 times more likely to agree, and participants 
with 13–14 years of education were 1.9 times 
more likely to agree). Age and gender were not significant 
predictors of attitudes. 
 
 
Predicting positive or negative opinion versus no opinion towards 
the acceptability of using drugs to treat depression. Since a 
substantial minority of participants offered no opinion (i.e. 
they answered ‘Don’t know’ or ‘Neutral’) on the acceptability 
of using prescription drugs to treat depression, we used a 
logistic regression analysis to identify the characteristics of 
participants that predicted whether they would offer an 
opinion on the issue. The full model was statistically significant 
(χ2 (7, n = 1251) = 83.38, p < 0.001). Table 2b shows 
that familiarity was a significant predictor – participants 
who had been treated for depression with prescription drugs 
were three times more likely to express a firm opinion 
about the acceptability of drug treatment and those who 
personally knew someone who had been treated were 2.4 
times more likely. Participants with 15 or more years of 
education were also significantly more likely to express an 
opinion than answer ‘Don’t know’ or remain neutral, than 
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participants with 1–10 years of education. Age and gender 
were not significant predictors. 
 
 
ADHD 
 
 
Familiarity. In contrast with depression, most (68.9%) participants 
did not know anyone who had been treated for 
ADHD using prescription drugs (‘Not familiar’); 28.7% 
knew someone who had been treated; only 2.5% had been 
treated themselves. Table 3 shows that, as with depression, 
a much higher proportion of people in the ‘Not familiar’ 
group answered ‘Don’t know’ (25.1%) compared to the two 
‘Familiar’ groups. Those in the ‘Not familiar’ group had the 
lowest rate of agreement with the acceptability of drug treatment 
for ADHD, although the ratio of agree-to-disagree 
responses was similar to those who personally knew someone 
who has undergone drug treatment for ADHD. 
 
 
Table 2. ‘It is acceptable for prescription drugs to be used in the treatment of 
depression’: (a) predictors of agreement with the statement; (b) predictors of 
having an opinion (vs ‘Don’t know’ / ‘Neutral’). 
 
 
 
Predicting positive attitudes towards the acceptability of drug 
treatment for ADHD.  
For ADHD, the full regression model 
was also statistically significant and able to distinguish 
between respondents who expressed outright agreement, 
and those who disagreed, with the use of drugs to treat 
ADHD (χ2 (7, n = 896) = 17.201, p < 0.05). Table 4a shows 
that only education was a significant predictor; familiarity, 
age and gender were not. Participants with 11–12, 13–14 
and 15+ years of education were all more likely to agree 
that drug treatment for ADHD is acceptable than those with 
1–10 years of education. 
 
Predicting positive or negative opinion versus no opinion towards 
the acceptability of drug treatment for ADHD. The full regression 
model was statistically significant (χ2 (7, n = 1251) = 
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72.518, p < 0.001) and, as with depression, Table 4b shows 
that gender was the only significant predictor – women 
were 1.5 times more likely to have an opinion than men. 
Age and education were not significant predictors of having 
an opinion about the acceptability of drug treatment for 
ADHD. Familiarity was a statistically significant predictor 
in this model. Those who personally knew someone who 
had undergone drug treatment for ADHD were 2.6 times 
more likely to have an opinion about the acceptability of 
drug treatment for ADHD compared to those in the ‘Not 
familiar’ group. Participants who had undergone drug treatment 
for ADHD were not significantly more likely to have 
an opinion about its acceptability compared to those in the 
‘Not familiar’ group. 
 
Table 3. Agreement with the statement ‘It is acceptable for prescription drugs 
to be used in the treatment of ADHD’ according to familiarity with treatment 
for ADHD with prescription drugs. 
 
 
Discussion 
Our survey found that most members of the public viewed 
drug treatment for depression as acceptable, while only a 
minority did not. Previous surveys of public attitudes have 
found that support for the use of anti-depressants has 
increased over time (Reavley and Jorm, 2011), and that 
people who view anti-depressants as harmful were less 
likely to know someone with the disorder (Jorm et al., 
2005; Reavley and Jorm, 2012). In our survey, participants 
who had either been treated for depression with prescription 
drugs or knew someone who had, were more likely to 
think drug treatment for depression is acceptable. People 
who were not familiar were also, perhaps appropriately, 
much more likely to reserve judgement and indicate that 
they did not know whether it is acceptable or not. 
 
Public attitudes were much less positive towards the use 
of drugs to treat ADHD – the proportion of participants in 
favour was almost equal to that who found it unacceptable. 
This may broadly reflect ongoing controversies in the public 
sphere about the potential over-diagnosis or overmedication 
of children with ADHD. Surveys with parents and 
educators have sometimes shown conflicting attitudes 
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towards the use of stimulants in the treatment of ADHD. 
 
While some surveys indicate that parents of children with 
ADHD are more likely to favour behavioural treatment, 
other studies have found that they view stimulants more 
positively (Corkum et al., 1999; McLeod et al., 2007; Stroh 
et al., 2008). This has made it difficult to ascertain whether 
objections to drug treatment for ADHD stem from those 
with personal experience with such treatments, or from 
those who are relatively unfamiliar with the disorder. Our 
results indicate that members of the general public are 
divided about the acceptability of drug treatment for 
ADHD, regardless of whether they have had personal contact 
with someone with ADHD or not. As with depression, 
we found that a large proportion of people with no personal 
contact with ADHD said that they did not know whether it 
was acceptable. Women were more likely than men to have 
a firm opinion about the acceptability of drug treatment, but 
were just as divided in their opinion as men. 
 
There are several strengths and limitations of this study. 
The sample size is large enough to make useful comparisons 
across relevant attitudinal and demographic categories, 
and the sample comprised a reasonably broad 
cross-section of the community. The ‘acceptability’ measure 
adds a useful contribution to the literature about public 
attitudes towards prescription drug treatment beyond 
 
 
measures of helpfulness or harmfulness. Furthermore, the 
survey compared public attitudes between two disorders 
and assessed personal familiarity, supporting previous evidence 
on the importance of personal experience in forming 
attitudes towards drug treatment of mental health problems. 
However, the representativeness of the sample was limited 
by the over-sampling of older participants from Queensland 
only, and the relatively low participation rate (31.9%). 
Gaining adequate participation from younger respondents 
when conducting CATI surveys using only randomly generated 
landline telephone samples has become more difficult 
as increasing numbers of young people use only mobile 
(cell) telephones, although US mobile/cell samples have 
been found to have a lower response rate (Hu et al., 2011). 
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Some studies have shown that the exclusion of mobile 
phone-only households does not significantly influence 
survey results (Pennay and Bishop, 2009). However, other 
studies have found that ‘landline’ and ‘mobile/cell’ samples 
differ in ways that may affect survey results (e.g. age; prevalence 
of health-related behaviours such as alcohol consumption 
or smoking) (Hu et al., 2011; Newman, 2011). 
 
Our survey results may be useful for practitioners and 
policy makers. At a broad level, it is important to understand 
how public attitudes towards pharmacological treatments 
for mental disorders align with those of prescribers. 
Negative attitudes towards drug treatment of ADHD may 
reduce a patient’s willingness to undergo or maintain drug 
treatment. Attitudes towards drug treatment are unlikely 
to be consistent across disorders. They are likely influenced 
by participants’ previous anecdotal experiences 
with drug treatment, including whether or not they know 
anyone who has undergone such treatment, as much as by 
media coverage. 
 
In our survey, the high proportion of ‘Don’t know’ 
responses among people without any personal contact with 
depression or ADHD may indicate that people’s attitudes 
towards the acceptability of drug treatment of these disorders 
are largely guided by personal or vicarious experiences. 
For ADHD and depression, people who answered 
‘Don’t know’ were less likely to know someone who had 
undergone drug treatment for the condition (and less likely 
to have received drug treatment themselves). It may be that 
many people who indicated ‘Don’t know’ felt that it was 
precisely because they lacked any personal contact with 
someone with ADHD or depression, that they were unable 
to make an informed judgement about whether drug treatment 
of those conditions was acceptable. Depression and 
ADHD are among the most common mental conditions in 
Australia, but members of the public who do not know anyone 
with the disorder may need particular information in 
the event that they (or their child) are diagnosed. Asking 
recently diagnosed patients whether they personally know 
anyone with the disorder (or know anyone who has undergone 
drug treatment for the disorder) may be a quick way 
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for doctors to raise the questions of prior knowledge of and 
attitudes towards drug treatment. 
 
Our results suggest the need for in-depth qualitative 
studies of public attitudes to better understand the reasons 
for beliefs about the acceptability of drug treatment for 
depression and ADHD. This would help to elucidate the 
commonly held beliefs underlying attitudes towards drug 
treatment and the factors that shape attitudes, particularly 
 
the influence of familiarity and anecdotal experiences with 
both disorders. For both depression and ADHD this would 
be useful in exploring the reasons people had for expressing 
outright disagreement with drug treatment. Our results 
indicate that the use of prescription anti-depressants is 
acceptable to most; however, we did not ask participants 
how different forms of treatment compared in terms of their 
acceptability. A number of studies have found that behavioural 
treatments or self-help for depression are often preferred 
to medication (Jorm et al., 2006; Reavley and Jorm, 
 
2011), although one recent study found that people who 
viewed anti-depressants as harmful were also likely to have 
less positive views about other forms of treatment (Reavley 
and Jorm, 2012). Less is known about attitudes towards the 
preferred methods of treatment for ADHD. Qualitative 
studies could build on this knowledge by exploring why 
drug treatment may be viewed as unacceptable or not the 
preferred method of treatment. 
 
 
Table 4. ‘It is acceptable for prescription drugs to be used in the treatment of 
ADHD’: (a) predictors of agreement with the 
statement; (b) predictors of having an opinion (vs ‘Don’t know’ / ‘Neutral’). 
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